Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) Overview | 7 | 1 |
| Therapeutics Development | 8 | 1 |
| Pipeline Products for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) Overview | 8 | 1 |
| Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) Therapeutics under Development by Companies | 9 | 1 |
| Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) Pipeline Products Glance | 10 | 4 |
| Late Stage Products | 10 | 1 |
| Clinical Stage Products | 11 | 1 |
| Early Stage Products | 12 | 1 |
| Unknown Stage Products | 13 | 1 |
| Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) Products under Development by Companies | 14 | 1 |
| Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) Companies Involved in Therapeutics Development | 15 | 11 |
| Alexion Pharmaceuticals, Inc. | 15 | 1 |
| AngioChem Inc. | 16 | 1 |
| ArmaGen Inc. | 17 | 1 |
| Bioasis Technologies Inc. | 18 | 1 |
| Green Cross Corporation | 19 | 1 |
| Inventiva | 20 | 1 |
| JCR Pharmaceuticals Co., Ltd. | 21 | 1 |
| Laboratorios Del Dr. Esteve S.A. | 22 | 1 |
| RegenxBio Inc. | 23 | 1 |
| Sangamo BioSciences, Inc. | 24 | 1 |
| Shire Plc | 25 | 1 |
| Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) Therapeutics Assessment | 26 | 9 |
| Assessment by Monotherapy Products | 26 | 1 |
| Assessment by Target | 27 | 2 |
| Assessment by Mechanism of Action | 29 | 2 |
| Assessment by Route of Administration | 31 | 2 |
| Assessment by Molecule Type | 33 | 2 |
| Drug Profiles | 35 | 19 |
| AGT-182 Drug Profile | 35 | 2 |
| EGT-301 Drug Profile | 37 | 1 |
| idursulfase Drug Profile | 38 | 2 |
| idursulfase beta Drug Profile | 40 | 2 |
| JR-032 Drug Profile | 42 | 1 |
| JR-141 Drug Profile | 43 | 1 |
| MTf-I2S Drug Profile | 44 | 1 |
| MTfp-I2S Drug Profile | 45 | 1 |
| odiparcil Drug Profile | 46 | 1 |
| pentosan polysulfate sodium Drug Profile | 47 | 1 |
| Recombinant Enzymes for Pompe, Fabry and Hunter Diseases Drug Profile | 48 | 1 |
| Recombinant Iduronate 2-Sulfatase Replacement for Mucopolysaccharidosis II Drug Profile | 49 | 1 |
| RGX-121 Drug Profile | 50 | 2 |
| SB-913 Drug Profile | 52 | 2 |
| Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) Dormant Projects | 54 | 1 |
| Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) Discontinued Products | 55 | 1 |
| Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) Product Development Milestones | 56 | 10 |
| Featured News &Press Releases | 56 | 1 |
| Apr 19, 2016: Preclinical Data from REGENXBIO s RGX-121 Gene Therapy Program to be Presented at the American Society of Gene &Cell Therapy 19th Annual Meeting | 56 | 1 |
| Feb 25, 2016: ESTEVE Provides Update On EGT-301 For Hunter Syndrome | 57 | 1 |
| Jul 31, 2015: Bioasis Announces the Successful Delivery to the CNS of an Enzyme used to Treat Hunter Syndrome | 57 | 1 |
| Jun 23, 2015: ACTSI-supports first-in-man clinical trial for Hunter syndrome at Emory University Hospital | 58 | 1 |
| Jun 15, 2015: ArmaGen Achieves Clinical Milestone in Hunter Syndrome Collaboration with Shire | 59 | 1 |
| Mar 10, 2015: PacificGMP and ArmaGen Announce Successful Manufacture of ArmaGen's investigational enzyme replacement therapy, AGT-182, for Phase 1 Clinical Trial | 59 | 1 |
| Dec 11, 2014: ArmaGen Announces FDA Acceptance of IND Application for AGT-182 for the Treatment of Hunter Syndrome | 60 | 1 |
| Sep 18, 2014: Bioasis Initiates MPS II Study with Renowned Lysosomal Storage Disease Expert Dr. Maurizio Scarpa and The Brains for Brain Foundation | 61 | 1 |
| Jun 17, 2014: ArmaGen Receives Notice of Allowance for U.S. Patent Covering Novel Investigational Therapy for Hunter Syndrome | 62 | 1 |
| Oct 02, 2013: Green Cross Exports Orphan Disease Drug Hunterase to Algeria | 62 | 1 |
| Jul 18, 2013: ARMAGEN Receives US Orphan Designation For Lead Product AGT-182 | 63 | 1 |
| Apr 08, 2013: Green Cross Announces Publication Of Clinical Trial Paper On Hunter Syndrome Drug Hunterase In International Scientific Press | 63 | 1 |
| Feb 18, 2013: Green Cross Receives FDA Orphan Drug Designation For Hunterase For Treatment Of Hunter Syndrome | 64 | 1 |
| Jan 10, 2012: Green Cross Receives Korean Approval For Hunterase | 65 | 1 |
| Oct 12, 2011: Green Cross Files Application For Korean Approval Of Hunterase For Treatment Of Hunter Syndrome | 65 | 1 |
| Appendix | 66 | 2 |
| Methodology | 66 | 1 |
| Coverage | 66 | 1 |
| Secondary Research | 66 | 1 |
| Primary Research | 66 | 1 |
| Expert Panel Validation | 66 | 1 |
| Contact Us | 66 | 1 |
| Disclaimer | 67 | 1 |